5-ethyl-3-(4-(2-methyl-4-propoxyphenyl)piperazin-1-yl)-1,2,4-oxadiazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 5-ethyl-3-(4-(2-methyl-4-propoxyphenyl)piperazin-1-yl)-1,2,4-oxadiazole
• 化学式: C₁₈H₂₆N₄O₂
• 分子量: 330.43
• InChiKey: MHNDUMDXMGPBQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.06
• 重原子数：
  24.0
• 可旋转键数：
  6.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  54.63
• 氢给体数：
  0.0
• 氢受体数：
  6.0

反应信息

• 作为产物：
  描述：

  4-氯-3-甲基苯酚 在 吡啶 、 甲基丙二酸亚异丙酯 、 chloro(2-dicyclohexylphosphino-2',4',6'-tri-i-propyl-1,1'-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II) methyl-t-butyl ether adduct 、 盐酸羟胺 、 caesium carbonate 、 三乙胺 、 N,N-二异丙基乙胺 、 三氟乙酸 、 sodium t-butanolate 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.5h， 生成 5-ethyl-3-(4-(2-methyl-4-propoxyphenyl)piperazin-1-yl)-1,2,4-oxadiazole
  参考文献：
  名称：

  Piperazine Oxadiazole Inhibitors of Acetyl-CoA Carboxylase

  摘要：

  Acetyl-CoA carboxylase (ACC) is a target of interest for the treatment of metabolic syndrome. Starting from a biphenyloxadiazole screening hit, a series of piperazine oxadiazole ACC inhibitors was developed. Initial pharmacokinetic liabilities of the piperazine oxadiazoles were overcome by blocking predicted sites of metabolism, resulting in compounds with suitable properties for further in vivo studies. Compound 26 was shown to inhibit malonyl-CoA production in an in vivo pharmacodynamic assay and was advanced to a long-term efficacy study. Prolonged dosing with compound 26 resulted in impaired glucose tolerance in diet-induced obese (DIO) CS7BL6 mice, an unexpected finding.

  DOI：

  10.1021/jm401601s

文献信息

• Piperazine Oxadiazole Inhibitors of Acetyl-CoA Carboxylase
  作者：Matthew P. Bourbeau、Aaron Siegmund、John G. Allen、Hong Shu、Christopher Fotsch、Michael D. Bartberger、Ki-Won Kim、Renee Komorowski、Melissa Graham、James Busby、Minghan Wang、James Meyer、Yang Xu、Kevin Salyers、Mark Fielden、Murielle M. Véniant、Wei Gu

  DOI：10.1021/jm401601s

  日期：2013.12.27

  Acetyl-CoA carboxylase (ACC) is a target of interest for the treatment of metabolic syndrome. Starting from a biphenyloxadiazole screening hit, a series of piperazine oxadiazole ACC inhibitors was developed. Initial pharmacokinetic liabilities of the piperazine oxadiazoles were overcome by blocking predicted sites of metabolism, resulting in compounds with suitable properties for further in vivo studies. Compound 26 was shown to inhibit malonyl-CoA production in an in vivo pharmacodynamic assay and was advanced to a long-term efficacy study. Prolonged dosing with compound 26 resulted in impaired glucose tolerance in diet-induced obese (DIO) CS7BL6 mice, an unexpected finding.